Dr. Krem discusses age-related and biological factors for low-grade lymphoma pathogenesis and outcomes. He then explains the mechanisms of action from low-grade lymphoma therapies.  He finishes by applying recent efficacy and toxicity data to older patients with low-grade lymphoma.